Literature DB >> 25349640

Severe alcoholic hepatitis-current concepts, diagnosis and treatment options.

Won Kim1, Dong Joon Kim1.   

Abstract

Alcoholic hepatitis (AH) is an acute hepatic manifestation occurring from heavy alcohol ingestion. Alcoholic steatohepatitis (ASH) is histologically characterized by steatosis, inflammation, and fibrosis in the liver. Despite the wide range of severity at presentation, those with severe ASH (Maddrey's discriminant function ≥ 32) typically present with fever, jaundice, and abdominal tenderness. Alcohol abstinence is the cornerstone of therapy for AH and, in the milder forms, is sufficient for clinical recovery. Severe ASH may progress to multi-organ failure including acute kidney injury and infection. Thus, infection and renal failure have a major impact on survival and should be closely monitored in patients with severe ASH. Patients with severe ASH have a reported short-term mortality of up to 40%-50%. Severe ASH at risk of early death should be identified by one of the available prognostic scoring systems before considering specific therapies. Corticosteroids are the mainstay of treatment for severe ASH. When corticosteroids are contraindicated, pentoxifylline may be alternatively used. Responsiveness to steroids should be assessed at day 7 and stopping rules based on Lille score should come into action. Strategically, future studies for patients with severe ASH should focus on suppressing inflammation based on cytokine profiles, balancing hepatocellular death and regeneration, limiting activation of the innate immune response, and maintaining gut mucosal integrity.

Entities:  

Keywords:  Alcoholic steatohepatitis; Corticosteroids; Infection; Pentoxifylline; Renal failure

Year:  2014        PMID: 25349640      PMCID: PMC4209414          DOI: 10.4254/wjh.v6.i10.688

Source DB:  PubMed          Journal:  World J Hepatol


  74 in total

Review 1.  Alcoholic liver disease.

Authors:  Robert S O'Shea; Srinivasan Dasarathy; Arthur J McCullough
Journal:  Hepatology       Date:  2010-01       Impact factor: 17.425

Review 2.  Alcoholic hepatitis.

Authors:  Michael R Lucey; Philippe Mathurin; Timothy R Morgan
Journal:  N Engl J Med       Date:  2009-06-25       Impact factor: 91.245

3.  Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor.

Authors:  Y Yamada; I Kirillova; J J Peschon; N Fausto
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

4.  Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial.

Authors:  Rafael Bañares; Frederik Nevens; Fin Stolze Larsen; Rajiv Jalan; Agustín Albillos; Matthias Dollinger; Faouzi Saliba; Tilman Sauerbruch; Sebastian Klammt; Johann Ockenga; Albert Pares; Julia Wendon; Tanja Brünnler; Ludwig Kramer; Philippe Mathurin; Manuel de la Mata; Antonio Gasbarrini; Beat Müllhaupt; Alexander Wilmer; Wim Laleman; Martin Eefsen; Sambit Sen; Alexander Zipprich; Teresa Tenorio; Marco Pavesi; Hartmut H-J Schmidt; Steffen Mitzner; Roger Williams; Vicente Arroyo
Journal:  Hepatology       Date:  2013-02-15       Impact factor: 17.425

5.  A histologic scoring system for prognosis of patients with alcoholic hepatitis.

Authors:  José Altamirano; Rosa Miquel; Aezam Katoonizadeh; Juan G Abraldes; Andrés Duarte-Rojo; Alexandre Louvet; Salvador Augustin; Rajeshwar P Mookerjee; Javier Michelena; Thomas C Smyrk; David Buob; Emmanuelle Leteurtre; Diego Rincón; Pablo Ruiz; Juan Carlos García-Pagán; Carmen Guerrero-Marquez; Patricia D Jones; A Sidney Barritt; Vicente Arroyo; Miquel Bruguera; Rafael Bañares; Pere Ginès; Juan Caballería; Tania Roskams; Frederik Nevens; Rajiv Jalan; Philippe Mathurin; Vijay H Shah; Ramón Bataller
Journal:  Gastroenterology       Date:  2014-01-15       Impact factor: 22.682

6.  Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial.

Authors:  E Akriviadis; R Botla; W Briggs; S Han; T Reynolds; O Shakil
Journal:  Gastroenterology       Date:  2000-12       Impact factor: 22.682

7.  Granulocyte colony-stimulating factor in severe alcoholic hepatitis: a randomized pilot study.

Authors:  Virendra Singh; Arun K Sharma; R Lakshmi Narasimhan; Ashish Bhalla; Navneet Sharma; Ratiram Sharma
Journal:  Am J Gastroenterol       Date:  2014-06-17       Impact factor: 10.864

8.  Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study.

Authors:  Irina A Kirpich; Natalia V Solovieva; Svetlana N Leikhter; Natalia A Shidakova; Oxsana V Lebedeva; Pavel I Sidorov; Tatjana A Bazhukova; Andrej G Soloviev; Shirish S Barve; Craig J McClain; Matt Cave
Journal:  Alcohol       Date:  2008-12       Impact factor: 2.405

9.  Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.

Authors:  Sunder Mudaliar; Robert R Henry; Arun J Sanyal; Linda Morrow; Hanns-Ulrich Marschall; Mark Kipnes; Luciano Adorini; Cathi I Sciacca; Paul Clopton; Erin Castelloe; Paul Dillon; Mark Pruzanski; David Shapiro
Journal:  Gastroenterology       Date:  2013-05-30       Impact factor: 22.682

10.  Spontaneous evolution in bilirubin levels predicts liver-related mortality in patients with alcoholic hepatitis.

Authors:  Minjong Lee; Won Kim; Yunhee Choi; Sunhee Kim; Donghee Kim; Su Jong Yu; Jeong-Hoon Lee; Hwi Young Kim; Yong Jin Jung; Byeong Gwan Kim; Yoon Jun Kim; Jung-Hwan Yoon; Kook Lae Lee; Hyo-Suk Lee
Journal:  PLoS One       Date:  2014-07-11       Impact factor: 3.240

View more
  9 in total

Review 1.  Multipotent mesenchymal stromal cells: A promising strategy to manage alcoholic liver disease.

Authors:  Fernando Ezquer; Flavia Bruna; Sebastián Calligaris; Paulette Conget; Marcelo Ezquer
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

2.  Point shear wave elastography predicts fibrosis severity and steatohepatitis in alcohol-related liver disease.

Authors:  Yuri Cho; Youn I Choi; Sohee Oh; Jimin Han; Sae Kyung Joo; Dong Hyeon Lee; Yong Jin Jung; Byeong Gwan Kim; Kook Lae Lee; Won Kim
Journal:  Hepatol Int       Date:  2019-12-19       Impact factor: 6.047

3.  Epithelial splicing regulatory protein 2-mediated alternative splicing reprograms hepatocytes in severe alcoholic hepatitis.

Authors:  Jeongeun Hyun; Zhaoli Sun; Ali Reza Ahmadi; Sushant Bangru; Ullas V Chembazhi; Kuo Du; Tianyi Chen; Hidekazu Tsukamoto; Ivan Rusyn; Auinash Kalsotra; Anna Mae Diehl
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

4.  Gutuo Jiejiu decoction improves survival of patients with severe alcoholic hepatitis: A retrospective cohort study.

Authors:  Hong-Yuan Mou; Hong-Ming Nie; Xiao-Yu Hu
Journal:  World J Gastroenterol       Date:  2017-04-28       Impact factor: 5.742

5.  Baseline urine metabolic phenotype in patients with severe alcoholic hepatitis and its association with outcome.

Authors:  Jaswinder Singh Maras; Sukanta Das; Shvetank Sharma; Saggere M Shasthry; Benoit Colsch; Christophe Junot; Richard Moreau; Shiv Kumar Sarin
Journal:  Hepatol Commun       Date:  2018-04-16

Review 6.  Alcoholic Hepatitis: Lost in Translation.

Authors:  Benjamin L Woolbright; Hartmut Jaeschke
Journal:  J Clin Transl Hepatol       Date:  2017-12-17

Review 7.  Liver regeneration and alcoholic liver disease.

Authors:  Yi Lv; Kwok Fai So; Jia Xiao
Journal:  Ann Transl Med       Date:  2020-04

8.  Iron-Overload triggers ADAM-17 mediated inflammation in Severe Alcoholic Hepatitis.

Authors:  Jaswinder Singh Maras; Sukanta Das; Sachin Sharma; Sukriti Sukriti; Jitendra Kumar; Ashish Kumar Vyas; Dhananjay Kumar; Adil Bhat; Gaurav Yadav; Manish Chandra Choudhary; Shvetank Sharma; Guresh Kumar; Chhagan Bihari; Nirupma Trehanpati; Rakhi Maiwall; Shiv Kumar Sarin
Journal:  Sci Rep       Date:  2018-07-06       Impact factor: 4.379

Review 9.  Acute-on-Chronic Liver Failure: Pathophysiological Mechanisms and Management.

Authors:  Arshi Khanam; Shyam Kottilil
Journal:  Front Med (Lausanne)       Date:  2021-11-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.